Skip to content

Clinical study for dexmedetomidine combined with parecoxib sodium on cognitive function in elderly patients after orthopedic surgery

Clinical study for dexmedetomidine combined with parecoxib sodium on cognitive function in elderly patients after orthopedic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800020149
Enrollment
Unknown
Registered
2018-12-17
Start date
2018-12-25
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative cognitive dysfunction

Interventions

A: Dexmedetomidine combined with parecoxib sodium

Sponsors

The Second Affiliated Hospital of Jiaxing Medical College
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Aged = 65 years old; (2) can communicate normally, can cooperate with and complete cognitive function test; (3) Anesthesia that agrees with general anesthesia; (4) Elective orthopedic surgery; (5) ASA I-III; (6) Patient informed consent.

Exclusion criteria

Exclusion criteria: (1) Those with a history of allergic reactions to non-steroidal drugs; (2) Those with cerebrovascular disease or have a history of brain diseases such as cerebral infarction, stroke and coronary heart disease history, etc.; (3) long-term use of analgesics or psychotropic drugs (including opioids, non-steroidal anti-inflammatory drugs, sedatives, antidepressants) and psychotropic substance abusers in patients with chronic pain or mental and neurological diseases; (4) Preoperative liver and kidney function (alanine aminotransferase, aspartate aminotransferase, urea nitrogen, creatinine) exceeds the normal value by 2 times; (5) Simplified mental state checklist (MMSE) preoperative examination <24 points; (6) History of neurological and psychological diseases including AD, Parkinson's, psychosis, etc.; (7) active gastrointestinal ulcers; (8) Take monoamine oxidase inhibitor or antidepressant within 15 days; (9) severe hearing or visual impairment; (10) Postoperative transfer to patients with intensive care unit (ICU); (11) pregnant women or mothers; (12) Anxiety or depression patients; (13) Disagree to participate in this study.

Design outcomes

Primary

MeasureTime frame
Postoperative cognitive dysfunction rate;Inflammatory factor;

Secondary

MeasureTime frame
VAS score;Adverse reactions;

Countries

China

Contacts

Public ContactJianPing Wu

The Second Affiliated Hospital of Jiaxing Medical College

w79373736@163.com+86 13967350495

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026